Current issues in the presentation of asymptomatic primary hyperparathyroidism: Proceedings of the fourth International Workshop

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 10, 2014, Pages 3580-3594

  Silverberg, Shonni J ^a   Clarke, Bart L ^b   Peacock, Munro ^c   Bandeira, Francisco ^d   Boutroy, Stephanie ^e   Cusano, Natalie E ^a   Dempster, David ^a   Lewiecki, E Michael ^f   Liu, Jian Min ^g   Minisola, Salvatore ^h   Rejnmark, Lars ⁱ   Silva, Barbara C ^j   Walker, Marcella D ^a   Bilezikian, John P ^a  

^a College of Physicians and Surgeons ^*  (United States)

^b MAYO CLINIC   (United States)

^c INDIANA UNIVERSITY   (United States)

^d FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^e UNIVERSITÉ DE LYON   (France)

^f UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^g SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^h SAPIENZA UNIVERSITY OF ROME   (Italy)

ⁱ AARHUS UNIVERSITY HOSPITAL   (Denmark)

^j FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; OSTEOCALCIN; PARATHYROID HORMONE; PROCOLLAGEN N PROTEINASE; RALOXIFENE;

BONE BIOPSY; BONE DENSITOMETRY; BONE DENSITY; BONE METABOLISM; CALCIUM BLOOD LEVEL; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CLINICAL EVALUATION; CLINICAL FEATURE; COGNITION; CONFERENCE PAPER; CORTICAL BONE; DUAL ENERGY X RAY ABSORPTIOMETRY; EVIDENCE BASED MEDICINE; FRACTURE; GEOGRAPHIC DISTRIBUTION; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; HYPERCALCEMIA; IMAGE QUALITY; KIDNEY CALCIFICATION; KIDNEY FUNCTION; MENTAL DISEASE; NEPHROLITHIASIS; NEUROPSYCHIATRY; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROIDECTOMY; PHENOTYPE; PRACTICE GUIDELINE; PRIMARY HYPERPARATHYROIDISM; QUALITY OF LIFE; RENOGRAPHY; SYSTEMATIC REVIEW; TRABECULAR BONE; TREATMENT INDICATION; TREATMENT PLANNING; VASCULAR DISEASE; WORKSHOP; ASYMPTOMATIC DISEASE; CONSENSUS DEVELOPMENT; EDUCATION; ENDOCRINOLOGY; HYPERPARATHYROIDISM, PRIMARY; STANDARDS;

ASYMPTOMATIC DISEASES; EDUCATION; ENDOCRINOLOGY; EVIDENCE-BASED MEDICINE; HUMANS; HYPERPARATHYROIDISM, PRIMARY;

EID: 84906656352     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-1415     Document Type: Conference Paper

References (110)

1. Bilezikian JP, Khan AA, Potts JT Jr. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Third International Workshop. J Clin Endocrinol Metab. 2009;94:335-339.
2. Silverberg SJ, Shane E, Jacobs TP, Siris E, Bilezikian JP. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med. 1999;341:1249-1255.
3. Rubin MR, Bilezikian JP, McMahon DJ, et al. The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab. 2008;93:3462-3470.
4. Eastell R, Brandi ML, Costa AG, D'Amour P, Shoback DM, Thakker RV. Diagnosis of Asymptomatic Primary Hyperparathyroidism: Proceedings of the Fourth International Workshop. J Clin Endocrinol Metab. 2014. 99:3570-3579.
5. Lundgren E, Rastad J, Thrufjell E, Akerström G, Ljunghall S. Population-based screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women. Surgery. 1997;121:287-294.
6. García-Martín A, Reyes-García R, Muñoz-Torres M. Normocalcemic primary hyperparathyroidism: one-year follow-up in one hundred postmenopausal women. Endocrine. 2012;42:764-766.
7. Cusano NE, Maalouf NM, Wang PY, et al. Normocalcemic hyperparathyroidism and hypoparathyroidism in two community-based nonreferral populations. J Clin Endocrinol Metab. 2013;98:2734-2741.
8. Lowe H, McMahon DJ, Rubin MR, Bilezikian JP, Silverberg SJ. Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J Clin Endocrinol Metab. 2007;92:3001-3005.
9. Tordjman KM, Greenman Y, Osher E, et al. Characterization of normocalcemic primary hyperparathyroidism. Am J Med. 2004;117:861-863.
10. Yeh MW, Ituarte PH, Zhou HC, et al. Incidence and prevalence of primary hyperparathyroidism in a racially mixed population. J Clin Endocrinol Metab. 2013;98:1122-1129.
11. De Lucia F, Minisola S, Romagnoli E, et al. Effect of gender and geographic location on the expression of primary hyperparathyroidism. J Endocrinol Invest. 2013;36:123-126.
12. Spivacow FR, Martínez C, Polonsky A. Primary hyperparathyroidism: postoperative long-term evolution [in Spanish]. Medicina (B Aires). 2010;70:408-414.
13. Bandeira F, Griz L, Caldas G, Bandeira C, Freese E. From mild to severe primary hyperparathyroidism: the Brazilian experience. Arq Bras Endocrinol Metabol. 2006;50:657-663.
14. Oliveira UE, Ohe MN, Santos RO, et al. Analysis of the diagnostic presentation profile, parathyroidectomy indication and bone mineral density follow-upof Brazilian patients with primary hyperparathyroidism. Braz J Med Biol Res. 2007;40:519-526.
15. Eufrasino C, Holanda N, Bandeira F. Epidemiology of primary hyperparathyroidism and its non-classical manifestations in the City of Recife, Brazil. Clin Med Insights Endocrinol Diabetes. 2013:6; 69-74.
16. Amaral LM, Queiroz DC, Marques TF, Mendes M, Bandeira F. Normocalcemic versus hypercalcemic primary hyperparathyroidism: more stone than bone? J Osteoporos. 2012;2012:128352.
17. Bilezikian JP, Meng X, Shi Y, Silverberg SJ. Primary hyperparathyroidism in women: a tale of two cities-New York and Beijing. Int J Fertil Womens Med. 2000;45:158-165.
18. Zhao L, Liu JM, He XY, et al. The changing clinical patterns of primary hyperparathyroidism in Chinese patients: data from 2000 to 2010 in a single clinical center. J Clin Endocrinol Metab. 2013;98:721-728.
19. Lo CY, Chan WF, Kung AW, Lam KY, Tam SC, Lam KS. Surgical treatment for primary hyperparathyroidism in Hong Kong: changes in clinical patterns over 3 decades. Arch Surg. 2004;139:77-82.
20. Pradeep PV, Jayashree B, Mishra A, Mishra SK. Systematic review of primary hyperparathyroidism in India: the past, present, and the future trends. Int J Endocrinol. 2011;2011:921814.
21. Malabu UH, Founda MA. Primary hyperparathyroidism in Saudi Arabia: a review of 46 cases. Med J Malaysia. 2007;62:394-397.
22. Prasarttong-Osoth P, Wathanaoran P, Imruetaicharoenchoke W, Rojananin S. Primary hyperparathyroidism: 11-year experience in a single institute in Thailand. Int J Endocrinol. 2012;2012:952426.
23. Hamidi S, Soltani A, Hedayat A, Kamalian N. Primary hyperparathyroidism: a review of 177 cases. Med Sci Monit. 2006;12:CR86-CR89.
24. Silverberg SJ, Shane E, de la Cruz L, et al. Skeletal disease in primary hyperparathyroidism. J Bone Miner Res. 1989;4:283-291.
25. Silverberg SJ, Locker FG, Bilezikian JP. Vertebral osteopenia: a new indication for surgery in primary hyperparathyroidism. J Clin Endocrinol Metab. 1996;81:4007-4012.
26. Wood K, Dhital S, Chen H, Sippel RS. What is the utility of distal forearm DXA in primary hyperparathyroidism? Oncologist. 2012;17:322-325.
27. Grey AB, Stapleton JP, Evans MC, Tatnell MA, Reid IR. Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism. A randomized, controlled trial. Ann Intern Med. 1996;125:360-368.
28. Khan AA, Bilezikian JP, Kung AW, et al. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2004;89:3319-3325.
29. Sankaran S, Gamble G, Bolland M, Reid IR, Grey A. Skeletal effects of interventions in mild primary hyperparathyroidism: a meta-analysis. J Clin Endocrinol Metab. 2010;95:1653-1662.
30. Peacock M, Bilezikian JP, Bolognese MA, et al. Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity. J Clin Endocrinol Metab. 2011;96:E9-E18.
31. Vasikaran S, Eastell R, Bruyère O, et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int. 2011;22:391-420.
32. Guo CY, Thomas WE, al-Dehaimi AW, Assiri AM, Eastell R. Longitudinal changes in bone mineral density and bone turnover in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab. 1996;81:3487-3491.
33. Christiansen P, Steiniche T, Brixen K, et al. Primary hyperparathyroidism: short-term changes in bone remodeling and bone mineral density following parathyroidectomy. Bone. 1999;25:237-244.
34. Guo CY, Holland PA, Jackson BF, et al. Immediate changes in biochemical markers of bone turnover and circulating interleukin-6 after parathyroidectomy for primary hyperparathyroidism. Eur J Endocrinol. 2000;142:451-459.
35. Stilgren LS, Hegedüs LM, Beck-Nielsen H, Abrahamsen B. Osteoprotegerin levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism. Calcif Tissue Int. 2003;73:210-216.
36. Ardawi MS, Al-Sibiany AM, Bakhsh TM, Rouzi AA, Qari MH. Decreased serum sclerostin levels in patients with primary hyperparathyroidism: a cross-sectional and a longitudinal study. Osteoporos Int. 2012;23(6):1789-1797.
37. Rubin MR, Lee KH, McMahon DJ, Silverberg SJ. Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab. 2003;88:1174-1178.
38. Faggiano A, Di Somma C, Ramundo V, et al. Cinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia and improves bone mineral density in patients with primary hyperparathyroidism. Endocrine. 2011;39:283-287.
39. Costa AG, Bilezikian JP. Bone turnover markers in primary hyperparathyroidism. J Clin Densitom. 2013;16:22-27.
40. Dempster DW, Parisien M, Silverberg SJ, et al. On the mechanism of cancellous bone preservation in postmenopausal women with mild primary hyperparathyroidism. J Clin Endocrinol Metab. 1999;84:1562-1566.
41. Vogel M, Hahn M, Delling G. Trabecular bone structure in patients with primary hyperparathyroidism. Virchows Arch. 1995;426:127-134.
42. Dempster DW, Müller R, Zhou H, et al. Preserved three-dimensional cancellous bone structure in mild primary hyperparathyroidism. Bone. 2007;41:19-24.
43. Parisien M, Cosman F, Mellish R W E et al. Bone structure in postmenopausal hyperparathyroid, osteoporotic, and normal women. J Bone Miner Res. 1995;10:1393-1399.
44. Steiniche T, Christiansen P, Vesterby A, et al. Primary hyperparathyroidism: bone structure, balance, and remodeling before and 3 years after surgical treatment. Bone. 2000;26:535-543.
45. Brockstedt H, Christiansen P, Mosekilde, et al. Reconstruction of cortical bonere modeling in untreated primary hyperparathyroidism and following surgery. Bone. 1995;16:109-117.
46. Zoehrer R, Dempster DW, Bilezikian JP, et al. Bone quality determined by Fourier transform infrared imaging analysis in mild primary hyperparathyroidism. J Clin Endocrinol Metab. 2008;93:3484-3489.
47. Roschger P, Dempster DW, Zhou H, et al. New observations on bone qualityin mild primary hyperparathyroidism as determined by quantitative backscattered electron imaging. J Bone Miner Res. 2007;22:717-723.
48. Chen Q, Kaji H, Iu MF, et al. Effects of an excess and a deficiency of endogenous parathyroid hormone on volumetric bone mineral density and bone geometry determined by peripheral quantitative computed tomography in female subjects. J Clin Endocrinol Metab. 2003;88:4655-4658.
49. Charopoulos I, Tournis S, Trovas G, et al. Effect of primary hyperparathyroidism on volumetric bone mineral density and bone geometry assessed by peripheral quantitative computed tomography in postmenopausal women. J Clin Endocrinol Metab. 2006;91:1748-1753.
50. Sornay-Rendu E, Boutroy S, Munoz F, Delmas PD. Alterations of cortical and trabecular architecture are associated with fractures in postmenopausal women, partially independent of decreased BMD measured by DXA: the OFELY study. J Bone Miner Res. 2007;22:425-433.
51. Szulc P, Boutroy S, Vilayphiou N, Chaitou A, Delmas PD, Chapurlat R. Cross-sectional analysis of the association between fragility fractures and bone microarchitecture in older men: the STRAMBO study. J Bone Miner Res. 2011;26:1358-1367.
52. Khosla S, Riggs BL, Atkinson EJ, et al. Effects of sex and age onbone microstructure at the ultradistal radius: a population-based noninvasive in vivo assessment. J Bone Miner Res. 2006;21:124-131.
53. Seeman E, Delmas PD, Hanley DA, et al. Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res. 2010;25:1886-1894.
54. Vilayphiou N, Boutroy S, Sornay-Rendu E, et al. Finite element analysis performed on radius and tibia HR-pQCT images and fragility fractures at all sites in postmenopausal women. Bone. 2010;46:1030-1037.
55. Hansen S, Beck Jensen JE, Rasmussen L, Hauge EM, Brixen K. Effects on bone geometry, density, and microarchitecture in the distal radius but not the tibia in women with primary hyperparathyroidism: a case-control study using HR-pQCT. J Bone Miner Res. 2010;25:1941-1947.
56. Hansen S, Hauge EM, Rasmussen L, Jensen JE, Brixen K. Parathyroidectomy improves bone geometry and microarchitecture in female patients with primary hyperparathyroidism: a one-year prospective controlled study using high-resolution peripheral quantitative computed tomography. J Bone Miner Res. 2012;27:1150-1158.
57. Vu TD, Wang XF, Wang Q, et al. New insights into the effects of primary hyperparathyroidism on the cortical and trabecular compartments of bone. Bone. 2013;55:57-63.
58. Stein EM, Silva BC, Boutroy S, et al. Primary hyperparathyroidism is associated with abnormal cortical and trabecular microstructure and reduced bone stiffness in postmenopausal women. J Bone Miner Res. 2013;28:1029-1040.
59. Pothuaud L, Carceller P, Hans D. Correlations between grey-level variations in 2D projection images (TBS) and 3D microarchitecture: applications in the study of human trabecular bone microarchitecture. Bone. 2008;42:775-787.
60. Hans D, Barthe N, Boutroy S, Pothuaud L, Winzenrieth R, Krieg MA. Correlations between trabecular bone score, measured using anteroposterior dual-energy x-ray absorptiometry acquisition, and 3-dimensional parameters of bone microarchitecture: an experimental study on human cadaver vertebrae. J Clin Densitom. 2011;14:302-312.
61. Hans D, Goertzen AL, Krieg MA, Leslie WD. Bone microarchitecture assessed by TBS predicts osteoporotic fractures independent of bone density: the Manitoba study. J Bone Miner Res. 2011;26:2762-2769.
62. Boutroy S, Hans D, Sornay-Rendu E, Vilayphiou N, Winzenrieth R, Chapurlat R. Trabecular bone score improves fracture risk predictioninnon-osteoporotic women: the OFELY study. Osteoporos Int. 2013;24:77-85.
63. Silva BC, Boutroy S, Zhang C, et al. Trabecular bone score (TBS)-a novel method to evaluate bone microarchitectural texture in patients with primary hyperparathyroidism. J Clin Endocrinol Metab. 2013;98:1963-1970.
64. Romagnoli E, Cipriani C, Nofroni I, et al. "Trabecular Bone Score" (TBS): an indirect measure of bone micro-architecture in postmenopausal patients with primary hyperparathyroidism. Bone. 2013;53:154-159.
65. Eller-Vainicher C, Filopanti M, Palmieri S, et al. Bone quality, as measured by trabecular bone score, in patients with primary hyperparathyroidism. Eur J Endocrinol. 2013;169:155-162.
66. Kenny AM, MacGillivray DC, Pilbeam CC, Crombie HD, Raisz LG. Fracture incidence in postmenopausal women with primary hyperparathyroidism. Surgery. 1995;118:109-114.
67. Khosla S, Melton LJ 3rd, Wermers RA, Crowson CS, O'Fallon Wm, Riggs Bl. Primary hyperparathyroidism and the risk of fracture: a population-based study. J Bone Miner Res. 1999;14:1700-1707.
68. Vestergaard P, Mollerup CL, Frøkjaer VG, Christiansen P, Blichert-Toft M, Mosekilde L. Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism. BMJ. 2000;321:598-602.
69. Larsson K, Ljunghall S, Krusemo UB, Naessén T, Lindh E, Persson I. The risk of hip fractures in patients with primary hyperparathyroidism: a population-based cohort study with a follow-up of 19 years. J Intern Med. 1993;234:585-593.
70. Vestergaard P, Mosekilde L. Parathyroid surgery is associated with a decreased risk of hip and upper arm fractures in primary hyperparathyroidism: a controlled cohort study. J Intern Med. 2004;255:108-114.
71. De Geronimo S, Romagnoli E, Diacinti D, D'Erasmo E, Minisola S. The risk of fractures in postmenopausal women with primary hyperparathyroidism. Eur J Endocrinol. 2006;155:415-420.
72. Vignali E, Viccica G, Diacinti D, et al. Morphometric vertebral fractures in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab. 2009;94:2306-2312.
73. Hernández JL, Olmos JM, Pariente E, et al. Influence of vitamin D status on vertebral fractures, bone mineral density, and bone turnover markers in normocalcemic postmenopausal women with high parathyroid hormone levels. J Clin Endocrinol Metab. 2013;98:1711-1717.
74. Cusano NE, Silverberg SJ, Bilezikian JP. Normocalcemic primary hyperparathyroidism. J Clin Densitom. 2013;16(1):33-39.
75. Koumakis E, Souberbielle JC, Sarfati E, et al. Bone mineral density evolution after successful parathyroidectomy in patients with normocalcemic primary hyperparathyroidism. J Clin Endocrinol Metab. 2013;98:3213-3220.
76. Peacock M. Primary hyperparathyroidism and the kidney: biochemical and clinical spectrum. J Bone Miner Res. 2002;17(suppl 2):N87-N94.
77. Witteveen JE, van Lierop AH, Papapoulos SE, Hamdy NA. Increased circulating levels of FGF23: an adaptive responsein primary hyperparathyroidism? Eur J Endocrinol. 2012;166:55-60.
78. Tassone F, Gianotti L, Emmolo I, Ghio M, Borretta G. Glomerular filtration rate and parathyroid hormone secretion in primary hyperparathyroidism. J Clin Endocrinol Metab. 2009;94:4458-4461.
79. Sorensen MD, Duh QY, Grogan RH, Tran TC, Stoller ML. Urinary parameters as predictors of primary hyperparathyroidism in patients with nephrolithiasis. J Urol. 2012;187:516-521.
80. Gudbjartsson DF, Holm H, Indridason OS, et al. Association of variants at UMOD with chronic kidney disease and kidney stonesrole of age and comorbid diseases. PLoS Genet. 2010;6:e1001039.
81. Evan AE, Lingeman JE, Coe FL, et al. Histopathology and surgical anatomy of patients with primary hyperparathyroidism and calcium phosphate stones. Kidney Int. 2008;74:223-229.
82. Yu N, Donnan PT, Flynn RW, et al. Increased mortality and morbidity in mild primary hyperparathyroid patients. The Parathyroid Epidemiology and Audit Research Study (PEARS). Clin Endocrinol (Oxf). 2010;73:30-34.
83. Yu N, Leese GP, Donnan PT. What predicts adverse outcomes in untreated primary hyperparathyroidism? The Parathyroid Epidemiologyand Audit Research Study (PEARS). Clin Endocrinol (Oxf). 2013;79:27-34.
84. Persson A, Bollerslev J, Rosen T, et al. Effect of surgery on cardiac structure and function in mild primary hyperparathyroidism. Clin Endocrinol Oxf. 2011;74:174-180.
85. Walker MD, Fleischer JB, Di Tullio MR, et al. Cardiac structure and diastolic function in mild primary hyperparathyroidism. J Clin Endocrinol Metab. 2010;95:2172-2179.
86. Iwata S, Walker MD, Di Tullio MR, et al. Aortic valve calcification in mild primary hyperparathyroidism. J Clin Endocrinol Metab. 2012;97:132-137.
87. Walker MD, Rundek T, Homma S, et al. Effect of parathyroidectomy on subclinical cardiovascular disease in mild primary hyperparathyroidism. Eur J Endocrinol. 2012;167:277-285.
88. Farahnak P, Ring M, Caidahl K, Farnebo LO, Eriksson MJ, Nilsson IL. Cardiac function in mild primary hyperparathyroidism and the outcome after parathyroidectomy. Eur J Endocrinol. 2010;163:461-467.
89. Kepez A, Harmanci A, Hazirolan T, et al. Evaluation of subclinical coronary atherosclerosis in mild asymptomatic primary hyperparathyroidism patients. Int J Cardiovasc Imaging. 2009;25:187-193.
90. Marini C, Giusti M, Armonino R, et al. Reduced coronary flow reserve in patients with primary hyperparathyroidism: a study by G-SPECT myocardial perfusion imaging. Eur J Nucl Med Mol Imaging. 2010;37:2256-2263.
91. Osto E, Fallo F, Pelizzo MR, et al. Coronary microvascular dysfunction induced by primary hyperparathyroidism is restored after parathyroidectomy. Circulation. 2012;126:1031-1039.
92. Rubin MR, Maurer MS, McMahon DJ, Bilezikian JP, Silverberg SJ. Arterial stiffness in mild primary hyperparathyroidism. J Clin Endocrinol Metab. 2005;90(6):3326-3330.
93. Tordjman KM, Yaron M, Izkhakov E, et al. Cardiovascular risk factors and arterial rigidity are similar in asymptomatic normocalcemic and hypercalcemic primary hyperparathyroidism. Eur J Endocrinol. 2010;162:925-933.
94. Walker MD, Fleischer J, Rundek T, et al. Carotid vascular abnormalities in primary hyperparathyroidism. J Clin Endocrinol Metab. 2009;94:3849-3856.
95. Farahnak P, Lärfars G, Sten-Linder M, Nilsson IL. Mild primary hyperparathyroidism: vitamin D deficiency and cardiovascular risk markers. J Clin Endocrinol Metab. 2011;96:2112-2118.
96. Bollerslev J, Rosen T, Mollerup CL, et al. Effect of surgery on cardiovascular risk factors in mild primary hyperparathyroidism. J Clin Endocrinol Metab. 2009;94:2255-2261.
97. Rao DS, Phillips ER, Divine GW, Talpos GB. Randomized controlled clinical trial of surgery versus no surgery in patients with mild asymptomatic primary hyperparathyroidism. J Clin Endocrinol Metab. 2004;89:5415-5422.
98. Bollerslev J, Jansson S, Mollerup CL, et al. Medical observation, compared with parathyroidectomy, for asymptomatic primary hyperparathyroidism: a prospective, randomized trial. J Clin Endocrinol Metab. 2007;92:1687-1692.
99. Ambrogini E, Cetani F, Cianferotti L, et al. Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trial. J Clin Endocrinol Metab. 2007;92:3114-3121.
100. Espiritu RP, Kearns AE, Vickers KS, Grant C, Ryu E, Wermers RA. Depression in primary hyperparathyroidism: prevalence and benefit of surgery. J Clin Endocrinol Metab. 2011;96:E1737-E1745.
101. Kahal H, Aye M, Rigby AS, Sathyapalan T, England RJ, Atkin SL. The effect of parathyroidectomy on neuropsychological symptoms and biochemical parameters in patients with asymptomatic primary hyperparathyroidism. Clin Endocrinol (Oxf). 2012;76:196-200.
102. Pasieka JL, Parsons L, Jones J. The long-term benefit of parathyroidectomy in primary hyperparathyroidism: a 10-year prospective surgical outcome study. Surgery. 2009;146:1006-1013.
103. Mihai R, Sadler GP. Pasieka's parathyroid symptoms scores correlate with SF-36 scores in patients undergoing surgery for primary hyperparathyroidism. World J Surg. 2008;32:807-814.
104. Amstrup AK, Rejnmark L, Mosekilde L. Patients with surgically cured primary hyperparathyroidism have a reduced quality of life compared with population-based healthy sex-, age-, and seasonmatched controls. Eur J Endocrinol. 2011;165:753-760.
105. Leong KJ, Sam RC, Garnham AW. Health-related quality of life improvement following surgical treatment of primary hyperparathyroidism in a United Kingdom population. Surgeon. 2010;8(1):5-8.
106. Walker MD, McMahon DJ, Inabnet WB, et al. Neuropsychological features in primary hyperparathyroidism: a prospective study. J Clin Endocrinol Metab. 2009;94:1951-1958.
107. Babinska D, Barczynski M, Stefaniak T, et al. Evaluation of selected cognitive functions before and after surgery for primary hyperparathyroidism. Langenbecks Arch Surg. 2012;397:825-831.
108. Perrier ND, Balachandran D, Wefel JS, et al. Prospective, randomized, controlled trial of parathyroidectomy versus observation in patients with "asymptomatic" primary hyperparathyroidism. Surgery. 2009;146:1116-1122.
109. Benge JF, Perrier ND, Massman PJ, Meyers CA, Kayl AE, Wefel JS. Cognitive and affective sequelae of primary hyperparathyroidism and early response to parathyroidectomy. J Int Neuropsychol Soc. 2009;15:1002-1011.
110. Roman SA, Sosa JA, Pietrzak RH, et al. The effects of serum calcium and parathyroid hormone changes on psychological and cognitive function in patients undergoing parathyroidectomy for primary hyperparathyroidism. Ann Surg. 2011;253:131-137.